Adding Enstilar to Taltz for plaque psoriasis
Part of Skin clinical trials.
This trial studies whether using Enstilar (a medicated skin spray/foam) together with Taltz works better than staying on Taltz alone for chronic plaque psoriasis. It focuses on adults with a specific amount of body skin affected by psoriasis who have already been on Taltz for at least 24 weeks.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult age 18 or older
- You have chronic plaque-type psoriasis (not just other types)
- Your psoriasis affects 3% to 8% of your body surface area
- You have been taking Taltz for at least 24 weeks
- If you can become pregnant, you must have a negative pregnancy test and use approved birth control during the study
- You must not be pregnant, breastfeeding, or planning pregnancy during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding Enstilar (a skin spray/foam medication) on top of your usual injection—Enbrel or Humira—works better for plaque psoriasis. You might be a candidate if your psoriasis affects a moderate amount of skin and you’ve been on Enbrel or Humira long enough.
This study compares two oral pill treatments—methotrexate and tofacitinib—for people with chronic plaque psoriasis that is moderate to severe and hasn't responded well to creams. The goal is to see which pill works better at clearing skin.
This trial tests a new medication called HSK44459 for people with moderate to severe plaque psoriasis who need systemic therapy (medicine that works throughout the body). The goal is to see if it is safe and effective.
This Phase 1 study tests a new drug (SFA002) in adults with stable plaque psoriasis. It mainly focuses on safety and how the body responds, and may eventually help people with psoriasis plaques.
This study tests an investigational oral medication called HS-10374 for moderate to severe plaque psoriasis. It aims to see how well it clears skin and prevents flares compared to a placebo, and if it is safe for long-term use.
This trial tests a new medication called HB0017 for moderate to severe plaque psoriasis. It aims to see if it is safe and effective in reducing skin symptoms and improving quality of life.
Hear when a new Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.